Study Phase 2

SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes

Trial Information

Generic NameGolimumabProduct NameSIMPONI®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassImmunosuppressantsPharmacological SubgroupImmunosuppressantsChemical SubgroupTumor Necrosis Factor Alpha (TNF-α) InhibitorsCondition StudiedDiabetes Mellitus, Type 1
Sponsor Protocol NumberCNTO148DML2001Enrollment84Data PartnerJohnson & Johnson% Female41.7%Mean/Median Age (Years)13.4% White85.7%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.